精华制药(002349) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was approximately ¥302.65 million, a decrease of 1.28% year-on-year, while revenue from the beginning of the year to the reporting period was approximately ¥939.72 million, an increase of 1.74%[9] - Net profit attributable to shareholders of the listed company was approximately -¥341.46 million, a decrease of 858.01% year-on-year, and the net profit for the year-to-date was approximately -¥212.91 million, down 223.65%[9] - Basic earnings per share were -¥0.4194, a decrease of 878.11% year-on-year[9] - Total operating revenue for Q3 2019 was CNY 302,653,319.48, a decrease of 1.5% compared to CNY 306,564,103.88 in the same period last year[59] - Net profit for Q3 2019 was a loss of CNY 343,644,613.61, compared to a profit of CNY 50,649,139.75 in Q3 2018, representing a significant decline[61] - The net profit attributable to the parent company was reported as -¥212,909,030.14, compared to a profit of ¥172,181,569.48 in the previous period, indicating a significant decline[79] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.32 billion, a decrease of 2.40% compared to the end of the previous year[9] - The company's total assets amounted to ¥3,318,248,063.87, down from ¥3,399,701,718.30, representing a decrease of approximately 2.4%[48] - The company's total liabilities increased to ¥838,427,184.84 from ¥705,268,671.55, which is an increase of approximately 18.9%[45] - The company’s total liabilities increased by 33.33% to ¥80,000,000.00 due to the reclassification of long-term borrowings to current liabilities[21] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., held 34.29% of the shares, totaling approximately 286.59 million shares[13] Cash Flow - The net cash flow from operating activities was approximately ¥141.79 million, an increase of 1,760.56% compared to the same period last year[9] - Cash and cash equivalents increased by 49.92% to ¥317,021,703.36 due to higher operating cash flow during the reporting period[21] - The company received cash inflows from operating activities totaling ¥966,611,280.39, compared to ¥871,321,206.76 in the previous period[95] - The net cash flow from investing activities was 6,369,306.10, a significant improvement from -3,699,370.90 in the previous period, suggesting better investment returns[103] - Cash and cash equivalents at the end of the period totaled 168,196,085.77, up from 57,211,583.14 in the previous period, indicating a strong liquidity position[106] Investment and Expenses - The company reported non-operating income and expenses, including government subsidies of approximately ¥2.61 million and investment income of approximately ¥8.10 million[9] - Investment income rose by 119.68% to ¥8,990,535.95, primarily from the equity investment in Wan Nian Chang Pharmaceutical[24] - The company reported a financial expense of ¥1,567,674.73, compared to a financial income of ¥88,240.63 in the previous period[70] - Research and development expenses for the quarter were CNY 9,687,756.39, an increase of 9.2% compared to CNY 8,876,315.80 in the previous year[59] - The company reported an asset impairment loss of ¥383,163,722.71, a 3196.49% increase, mainly due to goodwill impairment related to the acquisition of Nantong Dongli Management Co., Ltd.[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,216[13] - The company’s goodwill decreased by 67.04% to ¥187,906,805.57, reflecting impairment provisions taken during the reporting period[21] - The company reported a decrease in retained earnings to ¥391,762,781.47 from ¥644,629,950.75, a decline of approximately 39.2%[48]